This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
I am writing in response to the article entitled "Evaluation of Amikacin Sulfate: A New Aminoglycoside Antibiotic" (238:1547, 1977). The article offers an excellent view of this new drug currently available. Within the body of the article the author indicates, "Good usage of the aminoglycosides would seem to dictate that one of these two agents [tobramycin or gentamicin] be consistently selected by a physician when administration of this group of drugs is indicated and that the other aminoglycosides be reserved for use when resistance to the primary compounds is encountered." I suggest that many physicians who are in a busy practice may sometimes read only the abstracts of articles. Probably the most important point concerning the usage of amikacin is that this drug should be reserved for demonstrated resistance or situations when it is deemed highly likely that only this drug will be effective.In the majority
Hefelfinger DC. Amikacin Sulfate. JAMA. 1978;239(10):930–931. doi:10.1001/jama.1978.03280370026016
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: